Spots Global Cancer Trial Database for Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma

Official Title: Evaluation of the Effect of the Ocoxin®-Viusid® Nutritional Supplement on the Quality of Life of Patients With Metastatic Colorectal Adenocarcinoma. Phase II

Study ID: NCT03559543

Conditions

Colorectal Neoplasm

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasm

Rectal Diseases

Colonic Diseases

Intestinal Disease

Gastrointestinal Disease

Digestive System Disease

Interventions

Ocoxin-Viusid

Study Description

Brief Summary: The research product, registered as a nutritional supplement (Ocoxin®, oral solution), manufactured by Laboratorios Catalysis S. L., comes in the form of single-dose vials of 30 ml. It will be used at a rate of 60 ml daily (1 vial every 12 hours). Our main objective is To evaluate the effect of Ocoxin®-Viusid® on the quality of life of patients with metastatic colorectal adenocarcinoma. Our hypothesis is that the administration of the nutritional supplement Ocoxin®-Viusid® it is expected to improve the quality of life and enhance tolerance to chemotherapy in at least 70% of patients.

Detailed Description: * To evaluate the effect of Ocoxin®-Viusid® on the quality of life of patients. * To evaluate the influence of Ocoxin®-Viusid® on tolerance to onco-specific therapy. * Identify the changes that occur in the nutritional status of patients receiving the supplement. * To evaluate the toxicity of Ocoxin®-Viusid® in combination with chemotherapy in patients with metastatic colorectal adenocarcinoma.